Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and Axitinib in Metastatic Renal Cell Carcinoma
NCT04337970Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in renal cell carcinoma (RCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2020; status: completed.
02
Drugs
talazoparib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04337970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04337970.